Amgen Whale Trades Spotted
AMGNA whale with a lot of money to spend has taken a noticeably bearish stance on Amgen. Looking at options history for Amgen (NASDAQ:AMGN) we detected 22 strange trades.
A whale with a lot of money to spend has taken a noticeably bearish stance on Amgen. Looking at options history for Amgen (NASDAQ:AMGN) we detected 22 strange trades.
U.S. stocks traded higher, with the Dow Jones gaining more than 250 points on Monday. Here are some big stocks recording gains in today’s session.
Amgen, Inc. (NASDAQ: AMGN) shares are trading lower by 4.11% to $237.51 during Monday's pre-market session following FDA approval of Bristol Myers Squibb Co's (NYSE: BMY) plaque psoriasis drug Sotyktu, which s
Amgen's (NASDAQ:AMGN) short percent of float has fallen 7.95% since its last report. The company recently reported that it has 22.52 million shares sold short, which is 4.05% of all regular shares that are available for trading.
Amgen (NASDAQ:AMGN) has outperformed the market over the past 10 years by 1.04% on an annualized basis producing an average annual return of 12.67%. Currently, Amgen has a market capitalization of $124.75 billion.
U.S. indices traded higher Thursday despite a drop in U.S. GDP. Strength in stocks is possibly due to better-than-expected quarterly earnings from multiple companies as well as a rebound following a selloff earlier in the week.
A whale with a lot of money to spend has taken a noticeably bearish stance on Amgen. Looking at options history for Amgen (NASDAQ:AMGN) we detected 18 strange trades.
Piper Sandler has decided to maintain its Overweight rating of Amgen (NASDAQ:AMGN) and raise its price target from $255.00 to $260.00. Shares of Amgen are trading down 5.5% over the last 24 hours, at $235.12 per share. A move to $260.00 would account for a 10.58% increase from the current share price.
Amgen, Inc. (NASDAQ: AMGN) shares are trading lower by 6.21% at $233.33 after the company reported first-quarter earnings results.
Pulled from Benzinga Pro data, Amgen (NASDAQ:AMGN) posted Q1 earnings of $1.48 billion, an increase from Q4 of 22.27%. Sales dropped to $6.24 billion, a 8.88% decrease between quarters.
Within the last quarter, Amgen (NASDAQ:AMGN) has observed the following analyst ratings:
Amgen Inc (NASDAQ: AMGN) has recently received a notice of deficiency from the Internal Revenue Service centered on 2013 to 2015.